• LAST PRICE
    10.1200
  • TODAY'S CHANGE (%)
    Trending Down-0.6500 (-6.0353%)
  • Bid / Lots
    10.1000/ 6
  • Ask / Lots
    10.1200/ 1
  • Open / Previous Close
    10.6400 / 10.7700
  • Day Range
    Low 10.0200
    High 10.8700
  • 52 Week Range
    Low 6.4250
    High 19.2500
  • Volume
    470,121
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 10.77
TimeVolumeALLO
09:32 ET892710.63
09:33 ET150010.65
09:35 ET60010.79
09:37 ET262410.82
09:39 ET30010.825
09:42 ET115410.725
09:44 ET216510.635
09:46 ET123410.73
09:48 ET20010.71
09:50 ET123010.65
09:51 ET127010.6
09:53 ET252410.63
09:55 ET532610.63
09:57 ET50010.62
10:00 ET363710.67
10:02 ET30010.62
10:04 ET50010.645
10:06 ET190110.66
10:08 ET40010.65
10:09 ET79310.69
10:11 ET468010.64
10:13 ET240010.685
10:15 ET235710.685
10:18 ET560410.69
10:20 ET20010.71
10:22 ET1030310.7
10:24 ET250810.7
10:26 ET275810.68
10:27 ET368610.68
10:29 ET180010.6
10:31 ET375710.6
10:33 ET348510.58
10:36 ET70010.58
10:38 ET362110.56
10:40 ET377510.565
10:42 ET232610.59
10:44 ET30010.58
10:45 ET220010.53
10:47 ET26110.545
10:49 ET1702410.545
10:51 ET110010.53
10:54 ET403710.465
10:56 ET220010.49
10:58 ET279010.49
11:00 ET220010.45
11:02 ET125210.495
11:03 ET16010.4989
11:05 ET260010.46
11:07 ET247510.42
11:09 ET751210.41
11:12 ET80010.41
11:14 ET30010.4
11:16 ET296510.44
11:18 ET210510.405
11:20 ET158910.39
11:21 ET40010.4
11:23 ET30010.39
11:25 ET82610.41
11:27 ET20010.4
11:30 ET2669710.31
11:32 ET410310.33
11:34 ET20010.33
11:36 ET50010.33
11:38 ET40010.345
11:39 ET30010.33
11:41 ET40010.33
11:43 ET255510.28
11:45 ET1298810.27
11:48 ET3519510.16
11:50 ET190010.18
11:52 ET170010.165
11:54 ET1467810.14
11:56 ET309910.18
11:57 ET74510.18
11:59 ET283610.15
12:01 ET10010.13
12:03 ET683010.06
12:06 ET381310.08
12:08 ET90010.07
12:10 ET70010.04
12:12 ET90010.03
12:14 ET299810.02
12:15 ET129610.05
12:17 ET110010.09
12:19 ET190010.09
12:21 ET110010.14
12:24 ET701410.08
12:26 ET142710.1
12:28 ET150010.135
12:30 ET50010.1425
12:32 ET341510.13
12:33 ET70010.16
12:35 ET270210.145
12:37 ET392210.14
12:39 ET186010.155
12:42 ET120010.11
12:44 ET60010.13
12:46 ET180010.09
12:48 ET284910.07
12:50 ET40010.08
12:51 ET190910.08
12:53 ET245610.07
12:55 ET40010.07
12:57 ET120010.03
01:00 ET820010.045
01:02 ET722510.04
01:04 ET373810.105
01:06 ET50010.12
01:08 ET206910.15
01:09 ET321110.1
01:11 ET10010.08
01:13 ET50010.09
01:15 ET170010.12
01:18 ET410010.12
01:20 ET10010.129
01:22 ET63610.12
01:24 ET375110.09
01:26 ET58910.08
01:27 ET204410.115
01:29 ET30010.11
01:31 ET254010.115
01:33 ET121810.085
01:36 ET58510.08
01:38 ET94710.08
01:40 ET170910.11
01:42 ET85010.13
01:44 ET86910.12
01:45 ET150010.1
01:47 ET20010.12
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALLO
Allogene Therapeutics Inc
1.6B
-4.6x
---
United StatesALVO
Alvotech SA
1.5B
-2.1x
---
United StatesDICE
Dice Therapeutics Inc
1.6B
-16.2x
---
United StatesVTYX
Ventyx Biosciences Inc
1.6B
-15.2x
---
United StatesCLDX
Celldex Therapeutics Inc
1.6B
-14.6x
---
United StatesKYMR
Kymera Therapeutics Inc
1.5B
-9.4x
---
As of 2022-11-28

Company Information

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. It is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-715 plus nirogacestat, ALLO-605, ALLO-316, and ALLO-647.

Contact Information

Headquarters
210 E Grand AveSOUTH SAN FRANCISCO, CA, United States 94080-4811
Phone
650-457-2700
Fax
302-636-5454

Executives

Executive Chairman of the Board
Arie Belldegrun
President, Chief Executive Officer, Co-Founder, Director
David Chang
Co-Founder, Director
Joshua Kazam
Chief Financial Officer
Eric Schmidt
Chief People Officer
Susan Lundeen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.6B
Revenue (TTM)
$247.0K
Shares Outstanding
144.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.59
EPS
$-2.20
Book Value
$6.43
P/E Ratio
-4.6x
Price/Sales (TTM)
6,288.0
Price/Cash Flow (TTM)
---
Operating Margin
-126,707.70%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.